Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.04213-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Laurent Chorro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Vaccine Research and Development, Pearl River, New York, USA. Hauptthemen laut MEDLINE: O Antigens, Escherichia coli Infections, Escherichia coli, Glycoconjugates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
A US collection of invasive Escherichia coli serotype O1 bloodstream infection (BSI) isolates were assessed for genotypic and phenotypic diversity as the basis for designing a broadly protective O-antigen vaccine. Eighty percent of the BSI isolate serotype O1 strains were genotypically ST95 O1:K1:H7. The carbohydrate repeat unit structure of the O1a subtype was conserved in the three strains tested representing core genome multi-locus sequence types (MLST) sequence types ST95, ST38, and ST59. A long-chain O1a CRM 197 lattice glycoconjugate antigen was generated using oxidized polysaccharide and reductive amination chemistry. Two ST95 strains were investigated for use in opsonophagocytic assays (OPA) with immune sera from vaccinated animals and in murine lethal challenge models. Both strains were susceptible to OPA killing with O1a glycoconjugate post-immune sera. One of these, a neonatal sepsis strain, was found to be highly lethal in the murine challenge model for which virulence was shown to be dependent on the presence of the K1 capsule. Mice immunized with the O1a glycoconjugate were protected from challenges with this strain or a second, genotypically related, and similarly virulent neonatal isolate. This long-chain O1a CRM 197 lattice glycoconjugate shows promise as a component of a multi-valent vaccine to prevent invasive E. coli infections. IMPORTANCE The Escherichia coli serotype O1 O-antigen serogroup is a common cause of invasive bloodstream infections (BSI) in populations at risk such as newborns and the elderly. Sequencing of US BSI isolates and structural analysis of O polysaccharide antigens purified from strains that are representative of genotypic sub-groups confirmed the relevance of the O1a subtype as a vaccine antigen. O polysaccharide was purified from a strain engineered to produce long-chain O1a O-antigen and was chemically conjugated to CRM 197 carrier protein. The resulting glycoconjugate elicited functional antibodies and was protective in mice against lethal challenges with virulent K1-encapsulated O1a isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Vaccine Research and Development, Pearl River, New York, USA.
ORCID-Profile: Robert G K Donald
Förderung
- Pfizer Inc
Zitieren
APA
Chorro, L., Ndreu, D., Patel, A., Kodali, S., Li, Z., Keeney, D., Dutta, K., Sasmal, A., Illenberger, A., Torres, C. L., Pan, R., Silmon de Monerri, N. C., Chu, L., Simon, R., Anderson, A. S., & Donald, R. G. K. (2024). Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease. Microbiology Spectrum. https://doi.org/10.1128/spectrum.04213-23
Vancouver
Chorro L, Ndreu D, Patel A, Kodali S, Li Z, Keeney D, et al. Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease. Microbiology Spectrum. 2024. doi:10.1128/spectrum.04213-23
BibTeX
@article{Chorro2024,
author = {Chorro, Laurent and Ndreu, Duston and Patel, Axay and Kodali, Srinivas and Li, Zhenghui and Keeney, David and Dutta, Kaushik and Sasmal, Aniruddha and Illenberger, Arthur and Torres, C Lynn and Pan, Rosalind and Silmon de Monerri, Natalie C and Chu, Ling and Simon, Raphael and Anderson, Annaliesa S and Donald, Robert G K},
title = {Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.04213-23}
}
EUVIMED